Business Context and Reporting Period
This Form 8-K is a current report filed by Supernus Pharmaceuticals, Inc. on November 21, 2012, covering events occurring on November 19, 2012 and November 20, 2012. The filing reports significant regulatory and clinical developments regarding the Company's product pipeline.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Events
- Regulatory Milestone (Nov 19, 2012): The Company received confirmation from the U.S. Food and Drug Administration (FDA) that its product Oxtellar XR has been granted three years of market exclusivity.
- Clinical Development (Nov 20, 2012): The Company announced positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in patients with Attention Deficit Hyperactivity Disorder (ADHD).
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the reporting of the specific events listed above. The positive clinical results and market exclusivity grant are presented as favorable developments for the Company's pipeline.
Investor Verification Checklist
- Verify the specific terms and expiration date of the three-year market exclusivity granted for Oxtellar XR.
- Review the full details of the Phase IIb study results for SPN-810, including statistical significance and safety data, in the referenced press release (Exhibit 99.2).
- Confirm the regulatory pathway and timeline for potential Phase III trials or New Drug Application (NDA) submission for SPN-810 following the positive Phase IIb results.